166 related articles for article (PubMed ID: 22513979)
1. Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer.
Shankar J; Wiseman SM; Meng F; Kasaian K; Strugnell S; Mofid A; Gown A; Jones SJ; Nabi IR
J Pathol; 2012 Sep; 228(1):56-66. PubMed ID: 22513979
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.
Meng F; Joshi B; Nabi IR
PLoS One; 2015; 10(5):e0126056. PubMed ID: 25942420
[TBL] [Abstract][Full Text] [Related]
3. The investigation of galectin-3 in diseases of the thyroid gland.
Kovács RB; Földes J; Winkler G; Bodó M; Sápi Z
Eur J Endocrinol; 2003 Nov; 149(5):449-53. PubMed ID: 14585093
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
Ouyang D; Chen FJ; Wei MW; Yang AK; Chen ZQ; Li QL; Chen YF
Ai Zheng; 2005 Nov; 24(11):1367-71. PubMed ID: 16552965
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of galectin-3 in benign and malignant thyroid lesions.
Herrmann ME; LiVolsi VA; Pasha TL; Roberts SA; Wojcik EM; Baloch ZW
Arch Pathol Lab Med; 2002 Jun; 126(6):710-3. PubMed ID: 12033961
[TBL] [Abstract][Full Text] [Related]
6. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors.
Prasad ML; Pellegata NS; Huang Y; Nagaraja HN; de la Chapelle A; Kloos RT
Mod Pathol; 2005 Jan; 18(1):48-57. PubMed ID: 15272279
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study.
Kim SJ; Park JW; Yoon JS; Mok JO; Kim YJ; Park HK; Kim CH; Byun DW; Lee YJ; Jin SY; Suh KI; Yoo MH
J Korean Med Sci; 2004 Oct; 19(5):710-5. PubMed ID: 15483349
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
10. Galectin-3 cytotest in thyroid follicular neoplasia: a prospective, monoinstitutional study.
Pennelli G; Mian C; Pelizzo MR; Naccamulli D; Piotto A; Girelli ME; Mescoli C; Rugge M
Acta Cytol; 2009; 53(5):533-9. PubMed ID: 19798881
[TBL] [Abstract][Full Text] [Related]
11. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia.
Coli A; Bigotti G; Zucchetti F; Negro F; Massi G
Histopathology; 2002 Jan; 40(1):80-7. PubMed ID: 11903601
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
Matesa N; Samija I; Kusić Z
Cytopathology; 2007 Apr; 18(2):112-6. PubMed ID: 17397496
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of HBME-1, galectin-3, and β-catenin in poorly differentiated and anaplastic thyroid carcinomas.
Rossi ED; Straccia P; Palumbo M; Stigliano E; Revelli L; Lombardi CP; Santeusanio G; Pontecorvi A; Fadda G
Appl Immunohistochem Mol Morphol; 2013 May; 21(3):237-41. PubMed ID: 23235344
[TBL] [Abstract][Full Text] [Related]
15. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance].
Xu MR; Chen Y; Zhou SR; Chi MM; Chen SL; Liu LY
Zhonghua Zhong Liu Za Zhi; 2009 May; 31(5):356-60. PubMed ID: 19799084
[TBL] [Abstract][Full Text] [Related]
17. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer.
Sunaga N; Miyajima K; Suzuki M; Sato M; White MA; Ramirez RD; Shay JW; Gazdar AF; Minna JD
Cancer Res; 2004 Jun; 64(12):4277-85. PubMed ID: 15205342
[TBL] [Abstract][Full Text] [Related]
18. Aberrant l1 cell adhesion molecule affects tumor behavior and chemosensitivity in anaplastic thyroid carcinoma.
Kim KS; Min JK; Liang ZL; Lee K; Lee JU; Bae KH; Lee MH; Lee SE; Ryu MJ; Kim SJ; Kim YK; Choi MJ; Jo YS; Kim JM; Shong M
Clin Cancer Res; 2012 Jun; 18(11):3071-8. PubMed ID: 22472175
[TBL] [Abstract][Full Text] [Related]
19. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification of thyroid nodules by cytology.
Pagedar NA; Chen DH; Wasman JK; Savvides P; Schluchter MD; Wilhelm SM; Lavertu P
Laryngoscope; 2008 Apr; 118(4):692-6. PubMed ID: 18094649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
